Natriuretic peptide measurement as a screening test for overt and subclinical heart failure

International Journal of Cardiology

Volumn 92, Issue 1, 2003, Pages 9-15

  Nakamura, Motoyuki ^a   Hiramori, Katsuhiko ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Cost; General population; Heart failure; Natriuretic peptide; Screening

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AMINO TERMINAL SEQUENCE; BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HOSPITAL COST; HUMAN; HYPERTENSION; ISOTOPE LABELING; MASS SCREENING; PRACTICE GUIDELINE; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; SCREENING TEST; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 0242384127     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(03)00047-0     Document Type: Review

References (74)

1. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 88:1993;107-115.
2. MacIntyre K., Capewell S., Stewart S., et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66547 patients hospitalized between 1986 and 1995. Circulation. 102:2000;1126-1131.
3. Haldeman G.A., Croft J.B., Giles W.H., Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 137:1999;352-360.
4. Brown A.M., Cleland J.G. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 19:1998;1063-1069.
5. Rodriguez-Artalejo F., Guallar-Castillon P., Banegas J.R., del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J. 18:1997;1771-1779.
6. Reitsma J.B., Mosterd A., de Craen A.J., et al. Increase in hospital admission rates for heart failure in The Netherlands, 1980-1993. Heart. 76:1996;388-392.
7. Doughty R., Yee T., Sharpe N., MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-91. NZ Med J. 108:1995;473-475.
8. Davie A.P., Francis C.M., Love M.P., et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. Br Med J. 312:1996;222.
9. Kangawa K., Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun. 118:1984;131-139.
10. Sugawara A., Nakao K., Morii N., et al. Alpha-human atrial natriuretic polypeptide is released from the heart and circulates in the body. Biochem Biophys Res Comnun. 29:1985;439-446.
11. Raine A.E.G., Erne P., Burgisser E., et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. New Engl J Med. 315:1986;533-537.
12. Bates E.R., Shenker Y., Grekin R.J. The relationship between plasma levels of immunoreactive atrial natriuretic hormone and haemodynamic function in man. Circulation. 73:1986;1155-1161.
13. Mancini G.B.J., McGillen M.J., Bates E.R., Weder A.B., DeBoe S.F., Grekin R.J. Hormonal responses to cardiac tamponade: Inhibition of release of atrial natriuretic factor despite elevation or atrial pressures. Circulation. 76:1987;884-890.
14. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest. 87:1991;1402-1412.
15. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 87:1993;464-469.
16. Kohno M., Horio T., Yokokawa K., et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 92:1992;29-34.
17. Bettencourt P., Ferreira A., Sousa T., et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol. 69:1999;169-177.
18. Arakawa N., Nakamura M., Aoki H., Hiramori K. Relationship between plasma levels of brain natriuretic peptide and myocardial infarct size. Cardiology. 85:1994;334-340.
19. Morita E., Yasue H., Yoshimura M., et al. Increased plasma level of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 88:1993;82-91.
20. Mukoyama M., Nakao K., Saito Y., et al. Increased human brain natriuretic peptide in congestive heart failure. New Engl J Med. 323:1990;757-758.
21. Lerman A., Gibbons R.J., Rodeheffer R.J., et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 341:1993;1105-1109.
22. Buckley M.G., Marcus N.J., Yacoub M.H. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci. 97:1999;689-695.
23. Murdoch D.R., Byrne J., Morton J.J., McDonagh T.A., Robb S.D. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart. 78:1997;594-597.
24. Buckley M.G., Marcus N.J., Yacoub M.H., Singer D.R. Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice. Clin Sci. 95:1998;235-239.
25. Gobinet-Georges A., Valli N., Filliatre H., Dubernet M.F., Dedeystere O., Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med. 38:2000;519-523.
26. Maisel A.S., Koon J., Krishnaswamy P., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 141:2001;367-374.
27. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 37:2001;379-385.
28. Downie P.F., Talwar S., Squire I.B., Davies J.E., Barnett D.B., Ng L.L. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci. 97:1999;255-258.
29. Steele I.C., McDowell G., Moore A., et al. Responses of atrial natriuretic peptide and brain natriuretic peptide to exercise in patients with chronic heart failure and normal control subjects. Eur J Clin Invest. 27:1997;270-276.
30. McNairy M., Gardetto N., Clopton P., et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J. 143:2002;406-411.
31. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1349-1353.
32. Remes J., Miettinen H., Reunanen A., Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 12:1991;315-321.
33. Hobbs F.D., Davis R.C., Roalfe A.K., Hare R., Davies M.K., Kenkre J.E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Br Med J. 324:2002;1498-1500.
34. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 343:1994;440-444.
35. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Engl J Med. 347:2002;161-167.
36. Davidson N.C., Naas A.A., Hansom J.K., Kennedy N.S.J., Coutie W.J., Struthers A.D. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol. 77:1996;828-831.
37. Omland T., Aakvaag A., Vik-Mo H. Plasma cardiac natriuretic peptide determinations as a screening test for the detection of patients with mild left ventricular impairment. Heart. 76:1996;232-237.
38. Yamada Y., Goto J., Yokota M. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. Cardiology. 88:1997;4014-4017.
39. Suzuki T., Yamaoki K., Nakajima O., et al. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels. Jpn Heart J. 41:2000;205-214.
40. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 351:1998;9-13.
41. Arnlov J., Lind L., Stridsberg M., Andren B., Lithell H. N-terminal atrial natriuretic peptide and left ventricular geometry and function in a population sample of elderly males. J Intern Med. 247:2000;699-708.
42. Hetmanski D.J., Sparrow N.J., Curtis S., Cowley A.J. Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community. Heart. 84:2000;440-441.
43. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. J. Am. Med. Assoc. 288:2002;1252-1259.
44. Luchner A., Burnett J.C., Jougasaki M., et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 18:2000;1121-1128.
45. McClure S.J., Caruana L., Davie A.P., Goldthorp S., McMurray J.J. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. Br Med J. 317:1998;516-519.
46. Smith H., Pickering R.M., Struthers A., Simpson I., Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. Br Med J. 320:2000;906-908.
47. Marmot M.G. Interpretation of trends on coronary heart disease mortality. Acta Med Scand (Suppl). 701:1985;58-65.
48. Wallen T., Landahl S., Hedner T., Nakao K., Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart. 77:1997;264-267.
49. Wallen T., Landahl S., Hedner T., Hall C., Saito Y., Nakao K. Atrial natriuretic peptides predict mortality in the elderly. J Intern Med. 241:1997;269-275.
50. Iivanainen A.M., Tikkanen I., Tilvis R., Heikkila J., Helenius T., Kupari M. Associations between atrial natriuretic peptides, echocardiographic findings and mortality in an elderly population sample. J Intern Med. 241:1997;261-268.
51. McDonagh T.A., Cunningham A.D., Morrison C.E., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart. 86:2001;21-26.
52. Davis K.M., Fish L.C., Elahi D., Clark B.A., Minaker K.L. Atrial natriuretic peptide level in the prediction of congestive heart failure risk in frail elderly. J. Am. Med. Assoc. 267:1992;2625-2629.
53. Lang C.C., Prasad N., McAlpine H.M., et al. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. Am Heart J. 127:1994;1635-1636.
54. Yu C.M., Sanderson J.E., Shum I.O., et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J. 17:1996;1694-1702.
55. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 105:2002;595-601.
56. Hasegawa K., Fujiwara H., Doyama K., et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation. 88:1993;372-380.
57. Nishigaki K., Tomita M., Kagawa K., et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 28:1996;1234-1242.
58. Nakamura M., Niinuma H., Chiba M., et al. Effect of the maze procedure for atrial fibrillation on atrial and brain natriuretic peptide. Am J Cardiol. 79:1997;966-970.
59. Rossi A., Enriquez-Sarano M., Burnett J.C. Jr., Lerman A., Abel M.D., Seward J.B. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 35:2000;1256-1262.
60. Omland T. Biochemical detection of systolic dysfunction. Lancet. 351:1998;1063.
61. Struthers A.D. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart. 87:2002;97-98.
62. Daly C., Fox K., Henein M. Natriuretic peptides in the diagnosis of heart disease: first amongst equals? Int J Cardiol. 84:2002;107-113.
63. Niinuma H., Nakamura M., Hiramori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology. 90:1998;89-94.
64. Waku S., Iida N., Ishihara T. Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function. Methods Inf Med. 39:2000;249-253.
65. Ogawa K., Oida A., Sugimura H., et al. Clinical significance of blood brain natriuretic peptide level measurement in detection of heart disease in untreated outpatients. Circ J. 66:2002;122-126.
66. Nakamura M., Endo H., Nasu M., Arakawa N., Segawa T., Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart. 87:2002;131-135.
67. Margolis J.R., Kannel W.S., Feinleib M., Dawber T.R., McNamara P.M. Clinical features of unrecognized myocardial infarction - silent and symptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol. 32:1973;1-7.
68. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med. 325:1991;293-302.
69. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med. 327:1992;685-961.
70. Casale P.N., Devereux R.B., Milner M., et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 105:1986;173-178.
71. Kohno M., Horio T., Yokokawa K., et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med. 98:1995;257-265.
72. Muiesan M.L., Salvetti M., Rizzoni D., Castellano M., Donato F., Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 13:1995;1091-1095.
73. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C. Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 40:2002;976-982.
74. Wang T.J., Larson M.G., Levy D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 90:2002;254-258.